The effects of long-term psychoanalytic treatment on healthcare utilization and work impairment and their associated costs

Journal of Psychiatric Practice

Volumn 16, Issue 4, 2010, Pages 209-216

  Berghout, Caspar C ^a   Zevalkink, Jolien ^a,b   Hakkaart Van Roijen, Leona ^c  

^a Netherlands Psychoanalytic Institute   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cost offset; costs; Healthcare utilization; long term; psychoanalytic treatment; work impairment

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DYSTHYMIA; ECONOMIC EVALUATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRODUCTIVITY; PSYCHOANALYSIS;

ADULT; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; LONG-TERM CARE; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHOTHERAPY; TIME FACTORS; TREATMENT OUTCOME; WORKLOAD;

EID: 77954974053     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000386907.99536.75     Document Type: Article

References (34)

1. Leichsenring F, Rabung S. Effectiveness of long-term psychodynamic psychotherapy: A meta-analysis. JAMA 2008; 300:1551-1565
2. De Maat S, De Jonghe F, Schoevers R, et al. The effectiveness of long-term psychoanalytic therapy: A systematic review of empirical studies. Harv Rev Psychiatry 2009;17: 1-23.
3. Bateman A, Fonagy P. Health service utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. Am J Psychiatry 2003;160: 169-171
4. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001;158:295-302.
5. Luppa M, Heinrich S, Angermeyer MC, et al. Cost-of-illness studies of depression: A systematic review. J Affect Disord 2007;98:29-43.
6. Smit F, Bohlmeijer E, Cuijpers P.Wetenschappelijke onderbouwing depressiepreventie. Epidemiologie, aangrijpingspunten, huidige praktijk, nieuwe richtingen [Scientific underpinning for preventing depression. Epidemiology, focal points, current practice and new directions]. Utrecht: Trimbos-instituut; 2003.
7. Soeteman DI, Hakkaart-van Roijen L, Verheul R, et al. The economic burden of personality disorders in mental health care. J Clin Psychiatry 2008;69:259-265
8. Berghout C, Zevalkink J. Identifying clinical cases among patients assigned to psychoanalytic treatment. Bull Menninger Clin 2008;72:163-178
9. Zevalkink J, Berghout C. Mental health characteristics of patients assigned to long-term ambulatory psychoanalytic psychotherapy and psychoanalysis in the Netherlands. Psychother Res 2008;18:316-325
10. Willock B, Balzert C, Fayek A, et al. National health insurance coverage of psychoanalysis and psychotherapy: An international review highlighting some current issues. In: Kaley H, Eagle MN,Wolitzky DL, eds. Psychoanalytic therapy as health care. Effectiveness and economics in the 21st century. Hillsdale, NJ: The Analytic Press; 1999: 127-160
11. Zevalkink J. Indicatie-en behandelingsprotocol voor volwassenen [Protocol for treatment assignment and treatment progress in adult patients]. Amsterdam: Nederlands Psychoanalytisch Instituut; 2004.
12. De Maat S, Philipszoon F, Schoevers R, et al. Costs and benefits of long-term psychoanalytic therapy: Changes in health care use and work impairment. Harv Rev Psychiatry 2007;15:289-300.
13. Kraft S, Puschner B, Lambert MJ, et al. Medical utilization and treatment outcome in mid- and long-term outpatient psychotherapy. Psychother Res 2006;16:241-249
14. Beutel ME, Rasting M, Stuhr U, et al. Assessing the impact of psychoanalysis and long-term psychoanalytic therapies on health care utilization and costs. Psychother Res 2004;14:146-160
15. Lazar A, Sandell R, Grant J. Do psychoanalytic treatments have positive effects on health and health care utilization? Further findings of the Stockholm Outcome of Psychotherapy and Psychoanalysis Project (STOPPP). Psychother Res 2006;16:51-66.
16. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes, 3rd edition. New York: Oxford University Press; 2005.
17. Krupnick JL, Pincus HA. The cost-effectiveness of psychotherapy: A plan for research. Am J Psychiatry 1992; 149:1295-1305
18. Chiles JA, Lambert MJ, Hatch AL. The impact of psychological interventions on medical cost offset: A meta-analytic review. Clin Psychol Sci Pract 1999;6:204-220
19. Gabbard GO, Lazar SG, Hornberger J, et al. The economic impact of psychotherapy: A review. Am J Psychiatry 1997; 154:147-155
20. Hakkaart-van Roijen L, Bouwmans C. Handleiding Short Form-Health and Labour Questionnaire [Manual Short Form-Health and Labour Questionnaire]. Rotterdam: Institute for Medical Technology Assessment/Erasmus Universitair Medisch Centrum Rotterdam; 2007.
21. Leichsenring F. Randomized controlled versus naturalistic studies: A new research agenda. Bull Menninger Clin 2004;68:137-151
22. Sandell R, Blomberg J, Lazar A. When reality doesn't fit the blueprint: Doing research on psychoanalysis and long-term psychotherapy in a public health service program. Psychother Res 1997;7:333-344
23. Seligman MEP. The effectiveness of psychotherapy: The Consumer Reports Study. Am Psychol 1995;50:965-974
24. Centre for Evidence Based Medicine (CEBM). Levels of evidence Oxford: CEBM; March 2009 (available at www.cebm .net/index.aspx?o=1025, accessed October 6, 2009).
25. Berghout C, Zevalkink J, Hakkaart-van Roijen L. A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. Int J Technol Assess Health Care 2010;26: 3-10.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, third edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
27. American Psychiatric Association. Global Assessment of Functioning scale. In: Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000:32-34
28. Doidge N, Simon B, Brauer L, et al. Psychoanalytic patients in the U.S., Canada, and Australia: 1. DSM-III-R disorders, indications, previous treatment, medications, and length of treatment. J Am Psychoanal Assoc 2002;50:575-614.
29. Average exchange rate for 2006: 1 Euro = $1.25622 US dollars, based on historical exchange rates on the OANDA website www.oanda.com/currency/ historical-rates.
30. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek: Methoden en standaardprijzen voor economische evaluaties [Manual for cost research: Methods and unit-prices for economic evaluations]. Diemen: College voor zorgverzekeringen; 2004.
31. Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand 2004;110:383-392
32. Hakkaart-van Roijen L, van Straten A, Donker M, et al. Manual: Trimbos/iMTA questionnaire for costs associated with psychiatric illness (Tic-P)]. Rotterdam, The Netherlands: Institute for Medical Technology Assessment, Erasmus Universitair Medisch Centrum Rotterdam; May 2007 (available at www.imta.nl/publications/0796.pdf, accessed February 14, 2010).
33. van der Linden F, De Rijk A. Ziekteverzuim naar leeftijd en geslacht, 2002-2005 [Absenteeism by age and gender, 2002-2005]. Voorburg/Heerlen: Centraal Bureau voor Statistiek; 2008.
34. Cogan R, Porcerelli JH. Clinician reports of personality pathology of patients beginning and patients ending psychoanalysis. Psychol Psychother 2005;78:235-248